Buscar
Mostrando ítems 1-9 de 9
Artículo
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
(MDPI AG, 2022)
Abstract: A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced ...
Artículo
Stratification of patients in NASH clinical trials: a pitfall for trial success
(Elsevier, 2020)
Identifying the most effective therapeutic intervention in patients with NAFLD is challenging. Precise stratification in clinical trials is key to ensuring the inclusion of patients who will benefit (and not those who will ...
Artículo
Management of NAFLD patients with advanced fibrosis
(Wiley-Blackwell, 2021-06-21)
The prevalence of non alcoholic fatty liver disease (NAFLD) has increased to 25% in the general population and could double by 2030. Liver fibrosis is the main indicator of morbidity and mortality and recent estimations ...
Artículo
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
(Frontiers Media, 2021-11-24)
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has ...
Artículo
Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
(SPRINGER, 2022)
Background NAFLD clinical trials have shown suboptimal results, particularly for liver fibrosis, despite the robust preclinical drug development. We aimed to assess the histological response after the experimental treatment ...
Artículo
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
(Elsevier, 2022)
Background & Aims: Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation pro cess, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes ...
Artículo
Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models
(Aran Ediciones S.A., 2019)
Introduction: non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the developed world. Currently, there is no approved pharmacological therapy except for lifestyle intervention. Therefore, ...
Artículo
Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)
(Aran Ediciones S.A., 2019)
Background: recent evidence suggests a causal link between serum uric acid and the metabolic syndrome, dia betes me llitus, arterial hypertension, and renal and cardiac disease. Uric acid is an endogenous danger signal ...
Artículo
Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD
(Wiley, 2023)
Background and Aims Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition ...